Literature DB >> 1861205

Mumps outbreak in a highly vaccinated population.

B S Hersh1, P E Fine, W K Kent, S L Cochi, L H Kahn, E R Zell, P L Hays, C L Wood.   

Abstract

From October 1988 to April 1989, a large mumps outbreak occurred in Douglas County, Kansas. Of the 269 cases, 208 (77.3%) occurred among primary and secondary school students, of whom 203 (97.6%) had documentation of mumps vaccination. Attack rates were highest for students attending junior high school (8.0%), followed by high school (2.0%) and elementary school (0.7%). A retrospective cohort study conducted at one junior high school with an attack rate of 12.9% did not find age at vaccination or type of vaccine received (single or combined antigen) to be risk factors for vaccine failure. Students vaccinated more than 4 years before the outbreak appeared to have a higher attack rate than those vaccinated more recently (relative risk (RR) = 4.3; 95% confidence interval (CI) = 0.6, 30.0); however, this association did not exist when risk was evaluated based on number of vaccine doses received. Students who had documentation of receiving only one dose of vaccine were at greater risk than those who had received two doses (RR = 5.2; 95% CI = 1.0, 206.2). Overall, vaccine effectiveness among Douglas County junior high school students was estimated to be 83% (95% CI = 57%, 94%). These data suggest that mumps vaccine failure and the failure to vaccinate have contributed to the relative resurgence of mumps observed in the United States since 1986. The recent change in immunization policy to recommend a two-dose schedule of measles-mumps-rubella vaccine should help reduce the occurrence of mumps outbreaks in highly vaccinated populations.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1861205     DOI: 10.1016/s0022-3476(05)80726-7

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  36 in total

1.  Mumps: a current epidemiologic pattern as a necessary background for the choice of a vaccination strategy.

Authors:  C Zotti; O Ossola; R Barberis; A Castella; A M Ruggenini
Journal:  Eur J Epidemiol       Date:  1999-08       Impact factor: 8.082

2.  The control of mumps in Israel.

Authors:  P E Slater; E Anis; A Leventhal
Journal:  Eur J Epidemiol       Date:  1999-09       Impact factor: 8.082

3.  Interpreting serological surveys using mixture models: the seroepidemiology of measles, mumps and rubella in England and Wales at the beginning of the 21st century.

Authors:  A J Vyse; N J Gay; L M Hesketh; R Pebody; P Morgan-Capner; E Miller
Journal:  Epidemiol Infect       Date:  2006-05-02       Impact factor: 2.451

4.  Is mumps making a comeback?

Authors:  Jm Conly; Bl Johnston
Journal:  Can J Infect Dis Med Microbiol       Date:  2007-01       Impact factor: 2.471

5.  Safety and immunogenicity of a live attenuated mumps vaccine: a phase I clinical trial.

Authors:  Yan Liang; Jingchen Ma; Changgui Li; Yuguo Chen; Longding Liu; Yun Liao; Ying Zhang; Li Jiang; Xuan-Yi Wang; Yanchun Che; Wei Deng; Hong Li; Xiaoyu Cui; Na Ma; Dong Ding; Zhongping Xie; Pingfang Cui; Qiuyan Ji; JingJing Wang; Yuliang Zhao; Junzhi Wang; Qihan Li
Journal:  Hum Vaccin Immunother       Date:  2014-03-10       Impact factor: 3.452

6.  Comparison of the sensitivity of laboratory diagnostic methods from a well-characterized outbreak of mumps in New York city in 2009.

Authors:  Jennifer S Rota; Jennifer B Rosen; Margaret K Doll; Rebecca J McNall; Marcia McGrew; Nobia Williams; Elena N Lopareva; Albert E Barskey; Amado Punsalang; Paul A Rota; William R Oleszko; Carole J Hickman; Christopher M Zimmerman; William J Bellini
Journal:  Clin Vaccine Immunol       Date:  2013-01-16

7.  Characterization of large mumps outbreak among vaccinated Palestinian refugees.

Authors:  Musa Y Hindiyeh; Yair Aboudy; Mahmoud Wohoush; Lester M Shulman; Daniela Ram; Tal Levin; Tamar Frank; Flavia Riccardo; Mohamad Khalili; Elias-Shlash Sawalha; Maysoun Obeidi; Guido Sabatinelli; Zehava Grossman; Ella Mendelson
Journal:  J Clin Microbiol       Date:  2009-01-14       Impact factor: 5.948

8.  Risk factors for mumps at a university with a large mumps outbreak.

Authors:  Angela S Huang; Margaret M Cortese; Aaron T Curns; Rebecca H Bitsko; Hannah T Jordan; Fatma Soud; Jose Villalon-Gomez; Patricia M Denning; Kim A Ens; Gail R Hanson; Gustavo H Dayan
Journal:  Public Health Rep       Date:  2009 May-Jun       Impact factor: 2.792

9.  Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England.

Authors:  Cheryl Cohen; Joanne M White; Emma J Savage; Judith R Glynn; Yoon Choi; Nick Andrews; David Brown; Mary E Ramsay
Journal:  Emerg Infect Dis       Date:  2007-01       Impact factor: 6.883

10.  Prime-boost vaccination with recombinant mumps virus and recombinant vesicular stomatitis virus vectors elicits an enhanced human immunodeficiency virus type 1 Gag-specific cellular immune response in rhesus macaques.

Authors:  R Xu; F Nasar; S Megati; A Luckay; M Lee; S A Udem; J H Eldridge; M A Egan; E Emini; D K Clarke
Journal:  J Virol       Date:  2009-07-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.